NCT04091386View on ClinicalTrials.gov

Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)

CompletedOBSERVATIONAL
Enrollment

10

Participants

Timeline

Start Date

June 10, 2021

Primary Completion Date

May 7, 2024

Study Completion Date

July 5, 2024

Conditions
Hemophilia A
Interventions
DRUG

Damoctocog alfa pegol (Jivi, BAY94-9027)

Intervention is given as part of routine medical practice

Trial Locations (8)

70118

Tulane University, New Orleans

92868

Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders, Orange

Unknown

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Many Locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY